Discover how leveraging TLR7/8 agonists in combination with systemic IFN-I represents a promising strategy for treating melanoma.

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to treat pathology and symptoms of fragile X syndrome, ...